ReviewSaudi medical journal2014
The current status of beta blockers' use in the management of hypertension.
Review in Saudi medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Model-Based Virtual Clinical Trial Reveals Renal Impairment and Body Size as Key Determinants of Pharmacokinetic Variability and Drug-Drug Interaction Risk in Propranolol Therapy.Pharmaceutics · 2026Article
- Rate control treatment with calcium channel blockers and beta blockers for patients with atrial fibrillation: a systematic review and meta-analysis.European heart journal open · 2026Article
- Inappropriate use of propranolol among medical and dental students at the University of Jordan: cross-sectional study.Frontiers in medicine · 2025Article
- Atenolol Ameliorates Skeletal Muscle Atrophy and Oxidative Stress Induced by Cast Immobilization in Rats.Biomedicines · 2023Article
- Rapid Selective Detection and Quantification of β-Blockers Used in Doping Based on Molecularly Imprinted Nanoparticles (NanoMIPs).Polymers · 2022Article
- Temporal haemodynamic changes after bisoprolol treatment in patients with uncontrolled hypertension.Annals of translational medicine · 2021Article
- CRISPR/Cas9-mediated generation and analysis of N terminus polymorphic models of βMolecular therapy. Methods & clinical development · 2021Article
- Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.Drug design, development and therapy · 2021Article
- Colon adenocarcinoma-derived cells possessing stem cell function can be modulated using renin-angiotensin system inhibitors.PloS one · 2021Article
- Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level.Cureus · 2020Review
- Antidiabetics and antihypertensive medications use in Morocco: A pharmacoepidemiological descriptive study.African journal of primary health care & family medicine · 2020Article
- Non-antimicrobial pharmaceuticals can affect the development of antibiotic resistance in hospital wastewater.Environmental science and pollution research international · 2020Article
- Is the sigma-1 receptor a potential pharmacological target for cardiac pathologies? A systematic review.International journal of cardiology. Heart & vasculature · 2020Review
- Diuretic Activity of a Novel Peripherally-Restricted Orally-Active Kappa Opioid Receptor Agonist.Medical sciences (Basel, Switzerland) · 2019Article
- Immunologic adverse reactions of β-blockers and the skin.Experimental and therapeutic medicine · 2019Review
- Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.Metabolomics : Official journal of the Metabolomic Society · 2016Article
- In Vitro Effects of Propranolol on T Helper Type 1 Cytokine Profile in Human Leukemic T Cells.International journal of hematology-oncology and stem cell research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The invention of beta (β)-blockers culminated in a new era in the treatment of cardiovascular diseases (CD), and changed the course of pharmacology research for years to come. Since the introduction of propranolol into clinical practice in 1964, β-blockers enjoyed a special place in the clinicians' armamentarium against CDs, especially for patients with ischemic heart diseases, and are still one of the most extensively used therapeutic drugs in both cardiac and non-cardiac ailments. Current uses of β-blockers in CDs include ischemic heart diseases, hypertension, cardiac arrhythmias, and heart failure. Other substantial non-cardiac uses include glaucoma, migraine, situational anxiety, benign essential tremors, and cardiac symptoms of thyrotoxicosis. This review covers some of the evolutionary changes of clinical uses of β-blockers, the rationale for their use, some recent controversies surrounding their use for treatment of hypertension, and advantages of newer additions to the group.
Indexed as
Identifiers
25399206PMC4362137W1607319872What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.